BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25557636)

  • 1. CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment.
    Tamas K; Domanska UM; van Dijk TH; Timmer-Bosscha H; Havenga K; Karrenbeld A; Sluiter WJ; Beukema JC; van Vugt MA; de Vries EG; Hospers GA; Walenkamp AM
    Curr Pharm Des; 2015; 21(17):2276-83. PubMed ID: 25557636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.
    D'Alterio C; Avallone A; Tatangelo F; Delrio P; Pecori B; Cella L; Pelella A; D'Armiento FP; Carlomagno C; Bianco F; Silvestro L; Pacelli R; Napolitano M; Iaffaioli RV; Scala S
    Int J Cancer; 2014 Jul; 135(2):379-90. PubMed ID: 24375277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Inoue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2010 Aug; 17(8):2051-8. PubMed ID: 20177796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical evaluation of CXCL12-CXCR4 axis and VEGFR3 expression in primary urothelial cancer and its recurrence.
    Batsi O; Giannopoulou I; Nesseris I; Valavanis C; Gakiopoulou H; Patsouris ES; Arapandoni-Dadioti P; Lazaris AC
    Anticancer Res; 2014 Jul; 34(7):3537-42. PubMed ID: 24982366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression.
    Jiang YP; Wu XH; Shi B; Wu WX; Yin GR
    Gynecol Oncol; 2006 Oct; 103(1):226-33. PubMed ID: 16631235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemokine receptor CXCR4 and its ligand CXCL12 expressions and clinical significance in bladder cancer.
    Yang DL; Xin MM; Wang JS; Xu HY; Huo Q; Tang ZR; Wang HF
    Genet Mol Res; 2015 Dec; 14(4):17699-707. PubMed ID: 26782415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CXCL12 and its receptor CXCR4 in esophageal squamous cell carcinoma.
    Sasaki K; Natsugoe S; Ishigami S; Matsumoto M; Okumura H; Setoyama T; Uchikado Y; Kita Y; Tamotsu K; Hanazono K; Owaki T; Aikou T
    Oncol Rep; 2009 Jan; 21(1):65-71. PubMed ID: 19082444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of STAT3 is involved in malignancy mediated by CXCL12-CXCR4 signaling in human breast cancer.
    Liu X; Xiao Q; Bai X; Yu Z; Sun M; Zhao H; Mi X; Wang E; Yao W; Jin F; Zhao L; Ren J; Wei M
    Oncol Rep; 2014 Dec; 32(6):2760-8. PubMed ID: 25310198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 in primary cutaneous melanoma--biomarkers of potential utility?
    Mitchell B; Leone D; Feller K; Menon S; Bondzie P; Yang S; Park HY; Mahalingam M
    Hum Pathol; 2014 Oct; 45(10):2094-100. PubMed ID: 25130395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CXCL12/CXCR4 and its correlation to prognosis in esophageal squamous cell carcinoma.
    Wang DF; Lou N; Zeng CG; Zhang X; Chen FJ
    Ai Zheng; 2009 Feb; 28(2):154-8. PubMed ID: 19550128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma.
    Monteagudo C; Ramos D; Pellín-Carcelén A; Gil R; Callaghan RC; Martín JM; Alonso V; Murgui A; Navarro L; Calabuig S; López-Guerrero JA; Jordá E; Pellín A
    Clin Exp Metastasis; 2012 Aug; 29(6):625-37. PubMed ID: 22526457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the nuclear factor-κB signaling pathway in the regulation of CXC chemokine receptor-4 expression in neuroblastoma cells induced by tumor necrosis factor-α.
    Zhi Y; Lu H; Duan Y; Sun W; Guan G; Dong Q; Yang C
    Int J Mol Med; 2015 Feb; 35(2):349-57. PubMed ID: 25503960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL12, CXCR4 and CXCR7 expression in brain metastases.
    Salmaggi A; Maderna E; Calatozzolo C; Gaviani P; Canazza A; Milanesi I; Silvani A; DiMeco F; Carbone A; Pollo B
    Cancer Biol Ther; 2009 Sep; 8(17):1608-14. PubMed ID: 19625779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of chemokine CXCL12 and its receptor CXCR4 on proliferation, migration and invasion of epithelial ovarian cancer cells].
    Jiang YP; Wu XH; Xing HY; DU XY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):403-7. PubMed ID: 17697603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
    Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
    Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
    Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
    Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma.
    Rave-Fränk M; Tehrany N; Kitz J; Leu M; Weber HE; Burfeind P; Schliephake H; Canis M; Beissbarth T; Reichardt HM; Wolff HA
    Strahlenther Onkol; 2016 Jan; 192(1):47-54. PubMed ID: 26374452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer.
    de Oliveira KB; Guembarovski RL; Guembarovski AM; da Silva do Amaral Herrera AC; Sobrinho WJ; Ariza CB; Watanabe MA
    Clin Exp Med; 2013 Aug; 13(3):211-9. PubMed ID: 22699677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
    Arya M; Patel HR; McGurk C; Tatoud R; Klocker H; Masters J; Williamson M
    J Exp Ther Oncol; 2004 Dec; 4(4):291-303. PubMed ID: 15844659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors.
    Marques CS; Santos AR; Gameiro A; Correia J; Ferreira F
    BMC Cancer; 2018 Jul; 18(1):741. PubMed ID: 30012106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.